Introduction: Depressive illness has a high prevalence in patients undergoing coronary artery bypass graft surgery (CABG). The first line treatment for depression are selective serotonin reuptake inhibitors (SSRIs) which inhibit serotonin reuptake in the presynaptic neuronal membrane and uptake by platelets, inhibiting subsequent serotonin-mediated platelet activation. This presents a theoretically increased risk of bleeding and subsequent postoperative mortality. This review aims to investigate the effects of SSRIs on postoperative bleeding, defined as the need for transfusions and reoperation for bleeding, as well as 30-day mortality in patients undergoing CABG. Method: Four hundred and thirty-seven papers were screened with seven meeting the full inclusion criteria.
Introduction
The prevalence of depression in the general population of the UK has risen in the past two decades and continues to rise at a tremendous rate. The prevalence of major depression, as defined by the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition) criteria, in those attending general practice is estimated to be 13.9% for women and 8.5% for men. 1 Consequently, there has been a rise in antidepressant prescriptions between 2000 and 2011, with the number of prescriptions per 1000 population per day rising from 37.6 up to 70.6. 2 Significantly, patients with coronary artery disease have a higher prevalence of depression than the general population, estimated at between 20-40% of patients, with the highest rates of depression found in those awaiting coronary artery bypass graft surgery (CABG). 3 Depression has been shown to be associated with a higher risk of morbidity and mortality following acute coronary syndromes and subsequent cardiac surgery. Additionally, depressed patients have been found to be more likely to present with complications following cardiac surgery. 3 The current first line treatment for depressive illness and panic disorder are selective serotonin reuptake inhibitors (SSRIs). This class of drugs have their primary site of action via blockade of the serotonin transporter in cortical neurons and are now the first line of treatment due to their improved side effect profile and comparable efficacy to tricyclic antidepressants (TCAs). 4 SSRIs also influence platelet serotonin transport; platelets are unable to synthesise endogenous serotonin, therefore, the only means of acquiring it is through uptake from their environment, meaning the serotonin transporter is crucial for serotonin-mediated platelet activation and amplification. 5 This results in a theoretical increased risk of bleeding in those patients taking SSRIs undergoing cardiac surgery. Increased bleeding, in turn, leads to increased rates of transfusions, re-operation, infection and mortality. 6 Re-operation for bleeding has an incidence in the UK of around 2.4%, though it is associated with 1 in 10 deaths in patients undergoing CABG. 6 Re-exploration for bleeding has also been shown to be an independent predictor of post-operative mediastinitis and post-operative sternal wound infection. 7 The transfusion of red blood cells (RBC) carries a significant risk of immunological reactions, such as transfusion-associated acute lung injury, and has a significant correlation with higher mortality, particularly within the first 30 days. 8 These complications have an inevitable impact on the length of hospital stay.
The aims of this study were to address the following questions: (1) Is the use of SSRIs associated with increased bleeding complications following cardiac surgery? (2) Is the use of SSRIs associated with a higher rate of mortality and major adverse events following cardiac surgery? 
Materials and Methods

Search
Outcomes of interest
Analysis
A meta-analysis was performed in line with recommendations from PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-Analysis Of Observational Studies in Epidemiology). 9, 10 Review Manager (RevMan) Version 5.3, STATA Data Analysis and Statistical Software Version 14 and WinPepi Version 11:32 were used for the analyses. Random-effects models and fixed-effects models were used to aggregate the data; the odds ratio (OR) was used as the summary statistic for binary data. Studies reporting zero events for both SSRI and non-SSRI groups were excluded from the meta-analysis. Heterogeneity between studies was assessed using the I 2 value and χ 2 (Cochran's Q test) with publication bias being assessed by the use of funnel plots.
Quality assessment
Each study was assessed using a quality assessment score based on a modified Newcastle-Ottawa scale. The matching score was defined for each study by attributing one point for each pre-operative characteristic for which there was no statistically significant difference between the SSRI and non-SSRI groups. The modified Newcastle-Ottawa quality score was defined for each study using the subgroup criteria of 'selection' , 'comparability' and 'outcome assessment' and attributing stars to each study for these criteria.
Results
Seven studies were identified by systematic search to fulfil the inclusion criteria (Figure 1 ). [11] [12] [13] [14] [15] [16] [17] Studies were excluded on evaluation of methodology where there was no comparison of the two techniques. These studies included 146,811 patients, 8,978 of whom were in the SSRI group and 137,833 in the non-SSRI group. The search and data extraction were performed by two reviewers (ME and AS). The data extracted for both study groups included pre-operative characteristics, inclusion and exclusion criteria, matching criteria, quality assessment criteria, the transfusion of RBC, FFP and platelets, re-operation for bleeding and 30-day mortality. The two reviewers followed a pre-defined protocol and ultimately reached complete agreement for the search and data extraction. 
Outcomes
Transfusion of RBC. Requirement for (at least 1 unit of) RBC transfusion was reported by 5 studies. [11] [12] [13] 15, 16 There was a statistically higher rate of transfusion observed in the SSRI group using a random effects model (OR: 1.15; 95% CI: 1.06-1.26. Z=3.17, p=0.002) (Figure 2a) . No significant statistical heterogeneity was found between the studies (I 2 =0%). No publication bias is present on inspection of the funnel plot (Figure 2b) .
Transfusion of FFP.
A requirement for FFP transfusion was reported by 3 studies. 13, 15, 16 There was no statistically significant difference demonstrated between the SSRI and non-SSRI groups (OR: 0.96; 95% CI: 0.74-1.24; Z=0.31, p=0.75) (Figure 3) . Heterogeneity was raised (I 2 = 60%), however, the Cochrane Q test identified that the heterogeneity was not significant (χ 2 =4.98, df=2, p=0.08).
Transfusion of Platelets.
A requirement for platelet transfusion was reported by 3 studies. 13, 15, 16 There was no statistically significant difference demonstrated between the SSRI and non-SSRI groups (OR: 0.93; 95% CI: 0.79-1.09; Z=0.92, p=0.36) (Figure 4) . No significant statistical heterogeneity was found between the studies (I 2 =5%).
Re-operation for bleeding. This was reported by 3 studies. 13, 15, 16 There was no statistically significant difference demonstrated between the SSRI and non-SSRI groups (OR: 1.07; 95% CI: 0.66-1.74; Z=0.28, p=0.78) ( Figure  5 ). No significant statistical heterogeneity was found between the studies. (I 2 =0%).
30-day Mortality.
Mortality was reported by 5 studies. 11, [13] [14] [15] 17 There was no statistically significant difference demonstrated between the SSRI and non-SSRI groups (OR: 1.03; 95% CI: 0.90-1.17; Z=0.42, p=0.67) ( Figure 6 ). No significant statistical heterogeneity was found between the studies (I 2 =0%).
Discussion
We identified a total of 13 studies, with a further six excluded after closer scrutiny of the full text, resulting in seven papers suitable for inclusion in the systematic review and meta-analysis. [11] [12] [13] [14] [15] [16] [17] Our outcomes of interest consisted of RBC transfusion, FFP transfusion, platelet transfusion, re-operation due to bleeding and 30-day mortality in the SSRI group versus the non-SSRI group. Meta-analysis demonstrated that SSRI use increased the risk of RBC transfusion, but resulted in no difference in the rate of re-operation for bleeding. SSRI use had no effect on the rates of platelet or FFP transfusion nor on the 30-day mortality rate.
These results contrast with a previous meta-analysis investigating the effect of SSRIs in multiple surgical fields completed by Singh et al. in 2015. 18 Indeed, Singh et al. noted, in their CABG subgroup, that there was a significantly increased risk of mortality, but not of a requirement for blood transfusion. The reason that this study noted different results to our current study might be because the large retrospective cohort study by Gagne et al. 13 was not published in time for its inclusion. It is important to note that the Gagne study 13 is disproportionately the largest study in this analysis, with 132,686 patients. It utilises a national database and is, therefore, more representative of our population of interest and also unlikely to suffer from selection bias. It does also contribute almost 80% weight to the meta-analytical calculations. It is important to note the significant contribution of this study to the cohort of patients suffering from chronic renal failure and undergoing urgent or emergency or redo operations, all of which are significant confounding factors for the need for transfusion of red cells or blood products.
Studies investigating SSRIs and their relationship to upper gastrointestinal (GI) bleeding, 19 orthopaedic surgery 20 and breast surgery 21 have demonstrated variable results. Studies in upper GI bleeding noted that the risk of significant bleeding in patients taking SSRIs was exacerbated by the use of low dose aspirin or other nonsteroidal anti-inflammatories (NSAIDs). 19 This potential interaction is particularly concerning in patients undergoing coronary surgery.
Similar to the results of this meta-analysis, investigations in other specialties, such as orthopaedics, also noted a significantly increased risk of bleeding in patients who were prescribed SSRIs. 21 This indicates that the inhibition of platelet activation and aggregation as a result of SSRIs depletion of intracellular serotonin, that has been identified in preclinical and clinical studies, 22 translates into increased post-operative bleeding and a subsequent increased requirement for blood transfusion. A recently published study in CABG patients has demonstrated that, using specific markers of reduced platelet activity, mortality at 30 days is able to be predicted. 23 Re-operation as a result of excess bleeding has an incidence in the UK of ~2.4%, though it is associated with 1 in 10 deaths in patients undergoing CABG. 6 An association between transfusion and re-operation for bleeding has been observed, as has an association between transfusion and post-surgical mediastinitis. A recent study has identified a trend towards increased rates of post-operative sternal wound infection in patients with excessive bleeding. 7 Whilst our study has not demonstrated any increase in mortality related to the use of SSRIs, the significant increase in transfusion of RBC identified is concerning as there is a clear association between transfusion, morbidity and mortality.
The prevalence of depression in patients immediately before and after CABG surgery is believed to be between 30 and 40%. 4 However, the proportion of patients prescribed SSRIs in the studies that we identified was between 2.5% and 7.8%. [11] [12] [13] [14] [15] [16] [17] Although these populations may not be directly comparable, it implies that depression is under-diagnosed and under-treated in patients undergoing CABG and, therefore, our study population. Depression is known to be a risk factor for mortality in patients undergoing CABG; 24 also, a statistically significant association between untreated depression and non-compliance with secondary prevention has been identified by two different studies in patients with cardiovascular disease. 25, 26 In contrast, a later study by Stenman et al., investigating the CABG population, found no association between depression status before CABG and compliance with guidelinedirected medical therapy, the study acknowledged an increase in mortality although suggested an alternative mechanism may be responsible. 27 This under-diagnosis and subsequent placement of depressed patients into the comparator groups may have the effect of raising the number of adverse events in these groups, diminishing any observable effect SSRIs might be having on outcomes.
Conclusion
The pathophysiologies of both depression and postoperative bleeding leading to adverse outcomes are complex and isolating the relationship between SSRIs and post-operative bleeding is difficult. This systematic review and meta-analysis has demonstrated that SSRI use results in a significantly increased risk of requiring RBC transfusion; however, they have no effect on mortality. These results should be interpreted with caution as the studies identified were relatively heterogeneous in the preoperative demographics collected and adjusted for. Further study is required to identify if other outcomes are affected by SSRI use and subsequent transfusions.
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